Investment Panel: Attracting Investment & Securing Preclinical Funding for Early-Stage RNA Editing Therapeutic Candidates

• How is RNA editing viewed by investors and what are the directions for growth?

• How to successfully gain funding for preclinical candidates by demonstrating the right data

• What are the hurdles and pitfalls to starting an RNA Editing therapeutics company and what are the timelines, collaborations, and levels of investment required

Speakers:

Keay Nakae

Director of Research

Chardan

Roger Song

Senior Equity Research Analyst

Jefferies

Steve seedhouse

analyst

Cantor Fitzgerald

Peter Nell

Chief Execuitve Officer

Stealth Biotech